Progesterone News and Research

RSS

Plants too can make progesterone

In a finding that overturns conventional wisdom, scientists are reporting the first discovery of the female sex hormone progesterone in a plant. Until now, scientists thought that only animals could make progesterone. A steroid hormone secreted by the ovaries, progesterone prepares the uterus for pregnancy and maintains pregnancy. A synthetic version, progestin, is used in birth control pills and other medications. The discovery is reported in the American Chemical Society's Journal of Natural Products, a monthly publication.

5 Feb 2010

Researchers may have discovered how hormone progesterone prevents preterm birth

Researchers at Yale School of Medicine believe they may have discovered how the hormone progesterone acts to prevent preterm birth.

5 Feb 2010

USPTO issues three patents to Rosetta Genomics

Rosetta Genomics today announced that the United States Patent and Trademark Office (USPTO) has issued three patents to the company covering the composition of matter of human microRNAs.

4 Feb 2010

New neuroprotective drug trial for people with traumatic brain injuries

A clinical trial of a new neuroprotective drug for people with traumatic brain injuries will be offered to patients seen in UC Davis Medical Center's level-1 trauma center, through an $8 million grant funded by the Congressionally Directed Medical Research Program of the U.S. Department of Defense.

18 Jan 2010

Antares Pharma, Population Council report positive Phase 2 results for novel NES/E2 contraceptive gel

Antares Pharma, Inc. and the Population Council today announced successful results from a dose-finding Phase 2 trial for a novel contraceptive gel containing the progestin Nestorone and estradiol (NES/E2) utilizing the Antares ATD (advanced transdermal delivery) gel system. Based on this successful data, the two parties continue to expect to partner with a worldwide or regional pharmaceutical company in order to commercialize this novel contraceptive gel.

12 Jan 2010

Aneeve Nanotechnologies selected to work in the UCLA on-campus Technology Incubator Program

Aneeve Nanotechnologies LLC has been selected to work in the UCLA on-campus Technology Incubator Program at the California NanoSystems Institute. The startup company will conduct early-stage research for the development of a novel hormone sensor/meter for biomedical applications in the areas of infertility and menopause.

8 Jan 2010

Remedies to alleviate foot pain during pregnancy

"Oh my aching feet" is a phrase you hear often from pregnant women. But are sore feet a symptom they just must deal with during pregnancy? According to the American College of Foot and Ankle Surgeons (ACFAS) the answer is "no." There are many remedies available to help alleviate foot pain.

30 Dec 2009

Researchers recommend progesterone as viable treatment for traumatic brain injuries

Researchers at Emory University in Atlanta, GA, recommend that progesterone (PROG), a naturally occurring hormone found in both males and females that can protect damaged cells in the central and peripheral nervous systems, be considered a viable treatment option for traumatic brain injuries, according to a clinical perspective published in the January issue of the American Journal of Roentgenology.

23 Dec 2009

Results from five new studies on Genomic Health's Oncotype DX breast cancer test announced

Genomic Health, Inc. today announced results from five new studies on its Oncotype DX® breast cancer test, a multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit and recurrence risk for patients with early-stage breast cancer.

16 Dec 2009

Hormone therapy: An important treatment option for post-menopausal women

In connection with the New York Times’ recent coverage of hormone therapy1, Pfizer Inc. today released important facts and context to respond to the newspaper’s account. Pfizer believes the coverage is based on a misleading and selective reading of both the science and history of hormone therapy (HT) medicines.

14 Dec 2009

Results from clinical survey of Oncotype DX on patients with node-positive breast cancer announced

Genomic Health, Inc. today announced results from a clinical survey evaluating the impact of the Oncotype DX® Recurrence Score® result on physicians' adjuvant treatment recommendations for patients with node-positive, hormone receptor-positive breast cancer.

12 Dec 2009

New data suggests bisphosphonate drug may play a role in reducing recurrent breast cancer

Bisphosphonates are routinely given to women with postmenopausal breast cancer, but new data suggests that these agents may play a role in reducing recurrent breast cancer as well.

11 Dec 2009

Positive results from Genomic Health's Oncotype DX study in breast cancer patients with node-positive disease

Genomic Health, Inc. today announced that The Lancet Oncology published positive results from a study of Oncotype DX(®) in postmenopausal women with node-positive, estrogen receptor-positive breast cancer conducted by the Southwest Oncology Group (SWOG), a National Cancer Institute-supported clinical trials cooperative group.

11 Dec 2009

BHR Pharma files an IND for its BHR-100 intravenous progesterone infusion product

BHR Pharma, LLC (BHR) announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its proprietary BHR-100 intravenous progesterone infusion product.

8 Dec 2009

Social isolation and stress can raise breast cancer risk

Social isolation and related stress could contribute to human breast cancer susceptibility, research from a rat model designed at the University of Chicago to identify environmental mechanisms contributing to cancer risk shows.

8 Dec 2009

Genomic Health to present its Oncotype DX multi-gene expression test studies at the 32nd SABCS

Genomic Health, Inc. today announced that the company will present results from five studies at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), taking place December 9-13, 2009, at the Henry B. Gonzalez Convention Center.

5 Dec 2009

Results from Phase III pivotal study of FIRMAGON presented

Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurrence rate in a Phase III pivotal study of FIRMAGON® (monthly degarelix for injection) or monthly leuprolide in prostate cancer patients during the first year of treatment.

4 Dec 2009

Alpha-fetoprotein, a well-tolerated agent for treatment and prevention of breast cancer

Researchers have found that hormones produced during pregnancy induce a protein that directly inhibits the growth of breast cancer. This protein, alpha-fetoprotein (AFP), may serve as a viable, well-tolerated agent for the treatment and prevention of breast cancer, according to findings published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

25 Nov 2009

Serum progesterone concentration test can aid optimal timing of breast MRI in women with irregular periods

A simple blood test corresponding to the follicular phase (days 3-14) of a normal menstrual cycle can aid in optimal scheduling of breast MRI exams in premenopausal women with irregular cycles - possibly reducing the number of repeat scans and non-diagnostic tests patients experience and providing clearer images on which doctors make their recommendations, according to a study published in the December issue of the American Journal of Roentgenology.

21 Nov 2009

U.S. again scores 'D' for premature birth rate; states take action to reduce risk factors

For the second consecutive year, the United States earned only a "D" on the March of Dimes Premature Birth Report Card, demonstrating that more than half a million of our nation's newborns didn't get the healthy start they deserved.

17 Nov 2009